Ensysce Biosciences said it has completed enrollment in its second PF614-MPAR clinical study, marking a key milestone for the company’s abuse-resistant opioid technology. The trial, designated Part 3 of the PF614-MPAR program, evaluates the firm’s Multi-Pill Abuse Resistance platform designed to mitigate overdose risks associated with prescription opioids.
The study is supported by the National Institute on Drug Abuse under Award Number DA047682, reflecting federal backing for the initiative. PF614-MPAR holds Breakthrough Therapy status from regulators, streamlining its development pathway. Dr. Lynn Kirkpatrick, Ensysce’s CEO, said the enrollment completion advances a program aimed at addressing one of the most pressing safety challenges in opioid therapy.
Nearly 80,000 people in the U.S. die from opioid overdoses each year, according to federal data, underscoring the clinical and public health urgency behind abuse-resistant formulations. Ensysce’s MPAR technology is engineered to deter improper use while maintaining therapeutic efficacy, positioning the company within a growing niche of biotech firms targeting prescription drug safety.
